Vinay Prasad returns as FDA’s CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.
Vinay Prasad returns as FDA’s CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.
Copyright © Louis Velazquez. All Rights Reserved.